Suscripción a Biblioteca: Guest
Critical Reviews™ in Oncogenesis

Publicado 4 números por año

ISSN Imprimir: 0893-9675

ISSN En Línea: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Tumor Necrosis Factor-Alpha Gene Promoter (TNF-α G-308A) Polymorphisms Increase the Risk of Hepatocellular Carcinoma in Asians: A Meta-Analysis

Volumen 25, Edición 1, 2020, pp. 11-20
DOI: 10.1615/CritRevOncog.2020034846
Get accessGet access

SINOPSIS

Hepatocellular carcinoma (HCC) is one of the most common primary hepatic tumors, and it is ranked as the third most common cause of cancer-linked deaths. Although the precise etiology of HCC is unknown, inflammation has been considered the foremost cause of HCC. Previous studies indicated that tumor necrosis factor-alpha (TNF-α) is associated with increased risk of HCC, but the results are conflicting. In the present study, we assessed the correlation between TNF-α G-308A polymorphism as well as HCC risk via a meta-analysis. We searched databases such as PubMed, EMBASE, and Web of Science for articles related to this subject. To evaluate the correlation between TNF-α G-308A polymorphism and HCC, the odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Between-study heterogeneity was assessed using Cochrane Q test and I2 statistics. To assess the robustness of data, sensitivity analysis, publication bias, and subgroup analysis were conducted. Approximately 30 articles with 4,753 cases of HCC and 6,667 controls were included for the meta-analysis. Overall, the TNF-α G-308A polymorphism notably correlated with increased risk of HCC in the dominant model (OR = 1.41, 95% CI: 1.02-1.94, P = 0.036). Furthermore, a subgroup investigation showed significant correlation between TNF-α G-308A polymorphisms and HCC risk only in Asian populations (dominant model OR = 1.55, 95% CI: 1.05-2.23, P = 0.025). Studies in ethnic groups showed significant heterogeneity (I2 > 50%). Funnel plot and Eggers p values did not reveal publication bias. The present meta-analysis suggested that TNF-α G-308A polymorphisms are correlated with an elevated risk of HCC in Asian populations.

REFERENCIAS
  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394-424.

  2. Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22(3):141-50.

  3. Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: A review. J Hepatocellular Carcinoma. 2016;3:41-53.

  4. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinogen. 2017;16:1-1.

  5. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589-604.

  6. Kar P. Risk factors for hepatocellular carcinoma in India. J Clin Exper Hepatol. 2014;4(Suppl 3):S34-42.

  7. Dondeti MF, El-Maadawy EA, Talaat RM. Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms. World J Gastroenterol. 2016;22(30):6800-16.

  8. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F, Alesse E. The inflammatory microenvironment in hepatocellular carcinoma: A pivotal role for tumor-associated macrophages. BioMed Res Int. 2013;2013:187204-04.

  9. Refolo MG, Messa C, Guerra V, Carr BI, D'Alessandro R. Inflammatory mechanisms of HCC development. Cancers. 2020;12(3):641.

  10. Taniguchi T. Regulation of cytokine gene expression. Annu Rev Immunol. 1988;6:439-64.

  11. Jang MK, Kim HS, Chung YH. Clinical aspects of tumor necrosis factor-a signaling in hepatocellular carcinoma. Curr Pharm Des. 2014;20(17):2799-808.

  12. Li W, Jian YB. Antitumor necrosis factor-a antibodies as a novel therapy for hepatocellular carcinoma. Exper Therap Med. 2018;16(2):529-36.

  13. Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Segui B. The TNF paradox in cancer progression and immunotherapy. Frontiers Immunol. 2019;10(1818).

  14. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic trans-membrane protein: Ramifications for the complex physiology of TNF. Cell. 1988;53(1):45-53.

  15. Nedwin GE, Nay lor SL, Sakaguchi AY, Smith D, Jarrett-Nedwin J, Pennica D, Goeddel DV, Gray PW. Human lymphotoxin and tumor necrosis factor genes: Structure, homology and chromosomal localization. Nucleic Acids Res. 1985;13(17):6361-73.

  16. Knight JC, Udalova I, Hill AV, Greenwood BM, Peshu N, Marsh K, Kwiatkowski D. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nature Gen. 1999;22(2):145-50.

  17. Spriggs DR, Deutsch S, Kufe DW. Genomic structure, in-duction, and production of TNF-alpha. Immunol Series. 1992;56:3-34.

  18. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34(5):391-99.

  19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 2009;6(7):e1000100.

  20. Martorell-Marugan J, Toro-Dominguez D, Alarcon-Riquelme ME, Carmona-Saez P. MetaGenyo: A web tool for meta-analysis of genetic association studies. BMC Bioinform. 2017;18(1):563.

  21. Tsai JF, Chen SC, Lin ZY, Dai CY, Huang JF, Yu ML, Chuang WL. Independent and additive interaction between polymorphisms of tumor necrosis factor alpha-308 and lymphotoxin alpha+252 on risk of hepatocellular carcinoma related to hepatitis B. Kaohsiung J Med Sci. 2017;33(9):453-57.

  22. Li Y, Ou C, Shu H, Zhao H, Zhu B. The ERCC1- 4533/8092, TNF-alpha 238/308 polymorphisms and the risk of hepatocellular carcinoma in Guangxi Zhuang pop-ulations of China: Case-control study. Medicine (Baltimore). 2016;95(44):e5217.

  23. Aroucha DC, Carmo RF, Vasconcelos LR, Lima RE, Mendonca TF, Arnez LE, Cavalcanti Mdo S, Muniz MT, Aroucha ML, Siqueira ER, Pereira LB, Moura P, Pereira LM, Coelho MR. TNF-alpha and IL-10 polymorphisms increase the risk to hepatocellular carcinoma in HCV infected individuals. J Med Virol. 2016;88(9):1587-95.

  24. Shin SP, Kim NK, Kim JH, Lee JH, Kim JO, Cho SH, Park H, Kim MN, Rim KS, Hwang SG. Association between hepatocellular carcinoma and tumor necrosis factor alpha polymorphisms in South Korea. World J Gastroenterol. 2015;21(46):13064-72.

  25. Jin YJ, Lee D, Chung YH, Kim JA, Kim SE, Lee YS, Shin ES, Ryu SH, Jang MK, Lee JE, Park NH. Tumor necrosis factor-alpha gene polymorphism associated with development of hepatitis B virus-associated hepatocellular carcinoma. J Clin Gastroenterol. 2015;49(8):e76-e81.

  26. Sghaier I, Zidi S, Mouelhi L, Dabbech R, Ghazouani E, Brochot E, Stayoussef M, Yacoubi-Loueslati B. The relationship between TNF alpha gene polymorphisms (-238/-308), TNF RII VNTR (p75) and outcomes of hepatitis B virus infection in Tunisian population. Gene. 2015;568(2):140-45.

  27. El-Baz R, El-Rabat A, El-Moneim MA, Awadalla G. Interleukin-1beta and tumor necrosis factor-alpha genes polymorphism and hepatocellular carcinoma in patients with hepatitis C virus in Egyptian population. Indian J Appl Res. 2014;4(2):8-12.

  28. Feng H, Kuai JH, Zhang MY, Wang GC, Shi YJ, Zhang JY. Tumor necrosis factor-alpha gene -308G > A polymorphism alters the risk of hepatocellular carcinoma in a Han Chinese population. Diagn Pathol. 2014;9:199.

  29. Saxena R, Chawla YK, Verma I, Kaur J. IFN-gamma (+874) and not TNF-alpha (-308) is associated with HBV-HCC risk in India. Mol Cell Biochem. 2014;385(1-2):297-307.

  30. Teixeira AC, Mendes CT Jr, Marano LA, Deghaide NH, Secaf M, Elias J Jr, Muglia V, Donadi EA, Martinelli AL. Alleles and genotypes of polymorphisms of IL-18, TNF-alpha and IFN-gamma are associated with a higher risk and severity of hepatocellular carcinoma (HCC) in Brazil. Hum Immunol. 2013;74(8):1024-29.

  31. Radwan MI, Pasha HF, Mohamed RH, Hussien HI, El-Khshab MN. Influence of transforming growth factor-beta1 and tumor necrosis factor-alpha genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine. 2012;60(1):271-76.

  32. Shi HZ, Ren P, Lu QJ, Niedrgethmnn M, Wu GY. Association between EGF, TGF-beta1 and TNF-alpha gene polymorphisms and hepatocellular carcinoma. Asian Pac J Cancer Prev. 2012;13(12):6217-20.

  33. Yang Y, Qiu X, Yu H, Zeng X, Bei C. Correlation of polymorphism of TNF-a gene promoter with susceptibility to hepatocellular carcinoma in Guangxi. Exper Therap Med. 2012;3(3):513-18.

  34. Talaat RM, Esmail AA, Elwakil R, Gurgis AA, Nasr MI. Tumor necrosis factor-alpha -308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients. Chin J Cancer. 2012;31(1):29-35.

  35. Shi Z, Du C. Tumor necrosis factor alpha 308 G/A polymorphism and hepatocellular carcinoma risk in a Chinese population. Genet Test Mol Biomarkers. 2011;15(7-8):569-72.

  36. Chen X, Zhang L, Chang Y, Shen T, Wang L, Zhuang H, Lu F. Association of TNF-alpha genetic polymorphisms with hepatocellular carcinoma susceptibility: A case-control study in a Han Chinese population. Int J Biol Markers. 2011;26(3):181-87.

  37. Wang B, Wang J, Zheng Y, Zhou S, Zheng J, Wang F, Ma X, Zeng Z. A study of TNF-alpha-238 and -308 polymorphisms with different outcomes of persistent hepatitis B virus infection in China. Pathology. 2010;42(7):674-80.

  38. Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis. 2009;30(5):758-62.

  39. Akkiz H, Bayram S, Bekar A, Ozdil B, Akgollu E, Sumbul AT, Demiryurek H, Doran F. G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: Case-control study. Cancer Epidemiol. 2009;33(3-4):261-64.

  40. Jeng JE, Tsai HR, Chuang LY, Tsai JF, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY, Chang JG. Independent and additive interactive effects among tumor necrosis factor-alpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma. Medicine (Baltimore). 2009;88(6):349-57.

  41. Sakamoto T, Higaki Y, Hara M, Ichiba M, Horita M, Mizuta T, Eguchi Y, Yasutake T, Ozaki I, Yamamoto K, Onohara S, Kawazoe S, Shigematsu H, Koizumi S, Tanaka K. Interaction between interleukin-1beta -31T/C gene polymorphism and drinking and smoking habits on the risk of hepatocellular carcinoma among Japanese. Cancer Lett. 2008;271(1):98-104.

  42. Jeng JE, Tsai JF, Chuang LY, Ho MS, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY, Chang JG. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia. 2007;9(11):987-92.

  43. Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-DRB113 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat. 2007;14(12):841-48.

  44. Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, Yano K, Nagaoka S, Matsumoto T, Nakao K, Hamasaki K, Yatsuhashi H, Ishibashi H, Eguchi K. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection-association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol. 2005;42(4):505-10.

  45. Niro GA, Fontana R, Gioffreda D, Valvano MR, Lacobellis A, Facciorusso D, Andriulli A. Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int. 2005;25(6):1175-81.

  46. Chen CC, Yang SY, Liu CJ, Lin CL, Liaw YF, Lin SM, Lee SD, Chen PJ, Chen CJ, Yu MW. Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol. 2005;34(6):1310-18.

  47. Ho SY, Wang YJ, Chen HL, Chen CH, Chang CJ, Wang PJ, Chen HH, Guo HR. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha pro-moter gene. Cancer Causes Control. 2004;15(7):657-63.

  48. Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y, Omata M. Interleukin-1beta gene polymorphisms asso-ciated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology. 2003;37(1):65-71.

  49. Heneghan MA, Johnson PJ, Clare M, Ho S, Harrison PM, Donaldson PT. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Cancer. 2003;34(1):19-26.

  50. Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, Tur-Kaspa R, Klein T. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003;98(1):144-50.

  51. Qin H, Liu B, Shi T, Liu Y, Sun Y, Ma Y. Tumour necrosis factor-alpha polymorphisms and hepatocellular carcinoma: A meta-analysis. J Int Med Res. 2010;38(3): 760-68.

  52. Yang Y, Luo C, Feng R, Bi S. The TNF-a, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: A meta-analysis. J Cancer Res Clin Oncol. 2011;137(6):947-52.

  53. Wei Y, Liu F, Li B, Chen X, Ma Y, Yan L, Wen T, Xu M, Wang W, Yang J. Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: A HuGE systematic review and meta-analysis. Dig Dis Sci. 2011;56(8):2227-36.

  54. Hu Q, Lou GG, Liu YC, Qian L, Lv BD. The tumor ne-crosis factor-alpha-308 and -238 polymorphisms and risk of hepatocellular carcinoma for Asian populations: A meta-analysis. Curr Ther Res Clin Exp. 2014;76:70-75.

  55. Sun Q, Guo X, Wang Q, Zhao F. The association of TNF-308 (G/A) gene polymorphisms and hepatocellular carcinoma risk: A meta-analysis. Chinese J Cancer Res. 2016;28(5):536-42.

  56. Xiao Q, Fu B, Chen P, Liu ZZ, Wang W, Ye Q. Three poly-morphisms of tumor necrosis factor-alpha and hepatitis B virus related hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2016;95(50):e5609.

  57. Tavakolpour S, Sali S. Tumor necrosis factor-alpha-308 G/A polymorphisms and risk of hepatocellular carcinoma: A meta-analysis. Hepat Mon. 2016;16(4):e33537.

  58. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E86.

  59. Chen J-H, Wang Y-Y, Lv W-B, Gan Y, Chang W, Tian N-N, Huang X-H, Liu L, Yu X-F, Chen S-D. Effects of interactions between environmental factors and KIF1B genetic variants on the risk of hepatocellular carcinoma in a Chinese cohort. World J Gastroenterol. 2016;22(16):4183-90.

  60. Yu L-X, Ling Y, Wang H-Y. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol. 2018;2(1):6-6.

  61. Poli F, Nocco A, Berra S, Scalamogna M, Taioli E, Longhi E, Sirchia G. Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population. European J Immunogen. 2002;29(3):237-40.

  62. Selby S, Posch P TNF promoter region allele frequencies in the White population and their expression levels (34.11). J Immunol. 2010;184(1 Suppl):34.11.

  63. Lavu V, Venkatesan V, Bhaskar LV, Priyanka V, Kumarasamy P, Durairaj Paul SF, Rao SR. Polymorphic regions in Fc gamma receptor and tumor necrosis factor-alpha genes and susceptibility to chronic periodontitis in a cohort from south India. J Periodontol. 2016;87(8):914-22.

CITADO POR
  1. Sahu Tarun, Ratre Yashwant Kumar, Chauhan Sushma, Bhaskar L.V.K.S., Nair Maya P., Verma Henu Kumar, Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science, Journal of Drug Delivery Science and Technology, 63, 2021. Crossref

  2. Mercogliano María Florencia, Bruni Sofía, Mauro Florencia, Elizalde Patricia Virginia, Schillaci Roxana, Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy, Cancers, 13, 3, 2021. Crossref

  3. Sahu Tarun, Mehta Arundhati, Verma Henu Kumar, Bhaskar L.V.K.S., Multidrug resistance, a major obstacle in hepatocellular carcinoma treatment: challenges and future perspectives, in Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2, 2022. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain